Published in Acta Crystallogr Sect F Struct Biol Cryst Commun on May 31, 2006
Studies of Toxoplasma gondii and Plasmodium falciparum enoyl acyl carrier protein reductase and implications for the development of antiparasitic agents. Acta Crystallogr D Biol Crystallogr (2007) 0.98
Identification and development of novel inhibitors of Toxoplasma gondii enoyl reductase. J Med Chem (2010) 0.95
Type I and type II fatty acid biosynthesis in Eimeria tenella: enoyl reductase activity and structure. Parasitology (2007) 0.88
Novel type II fatty acid biosynthesis (FAS II) inhibitors as multistage antimalarial agents. ChemMedChem (2013) 0.87
Discrimination of potent inhibitors of Toxoplasma gondii enoyl-acyl carrier protein reductase by a thermal shift assay. Biochemistry (2013) 0.77
Modification of triclosan scaffold in search of improved inhibitors for enoyl-acyl carrier protein (ACP) reductase in Toxoplasma gondii. ChemMedChem (2013) 0.77
Food-related illness and death in the United States. Emerg Infect Dis (1999) 39.22
Chemical and biological evolution of nucleotide-binding protein. Nature (1974) 7.39
Toxoplasma gondii: transmission, diagnosis and prevention. Clin Microbiol Infect (2002) 3.84
Controlled intracellular processing of fusion proteins by TEV protease. Protein Expr Purif (2000) 2.38
Triclosan inhibits the growth of Plasmodium falciparum and Toxoplasma gondii by inhibition of apicomplexan Fab I. Int J Parasitol (2001) 1.72
Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI). J Med Chem (2002) 1.44
Delivery of antimicrobials into parasites. Proc Natl Acad Sci U S A (2003) 1.31
Molecular basis for triclosan activity involves a flipping loop in the active site. Protein Sci (1999) 1.30
A study of the structure-activity relationship for diazaborine inhibition of Escherichia coli enoyl-ACP reductase. J Mol Biol (2001) 1.21
Toxoplasma gondii: perfecting an intracellular life style. Traffic (2003) 1.19
Expression, purification and crystallization of the Plasmodium falciparum enoyl reductase. Acta Crystallogr D Biol Crystallogr (2003) 1.09
Inhibitor binding studies on enoyl reductase reveal conformational changes related to substrate recognition. J Biol Chem (1999) 1.09
Economic losses caused by foodborne parasitic diseases. Parasitol Today (1994) 1.08
Structural basis for the variation in triclosan affinity to enoyl reductases. J Mol Biol (2004) 1.05
An inhibitor of FtsZ with potent and selective anti-staphylococcal activity. Science (2008) 3.21
Risk factors for Toxoplasma gondii infection in mothers of infants with congenital toxoplasmosis: Implications for prenatal management and screening. Am J Obstet Gynecol (2005) 2.66
Dectin-1 and TLRs permit macrophages to distinguish between different Aspergillus fumigatus cellular states. J Immunol (2006) 2.43
Unrecognized ingestion of Toxoplasma gondii oocysts leads to congenital toxoplasmosis and causes epidemics in North America. Clin Infect Dis (2011) 1.87
Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans. Vaccine (2010) 1.61
Toxoplasma gondii tachyzoite-bradyzoite interconversion. Trends Parasitol (2002) 1.58
Structural studies of fatty acyl-(acyl carrier protein) thioesters reveal a hydrophobic binding cavity that can expand to fit longer substrates. J Mol Biol (2006) 1.48
NALP1 influences susceptibility to human congenital toxoplasmosis, proinflammatory cytokine response, and fate of Toxoplasma gondii-infected monocytic cells. Infect Immun (2010) 1.46
Evolutionary origins of the eukaryotic shikimate pathway: gene fusions, horizontal gene transfer, and endosymbiotic replacements. Eukaryot Cell (2006) 1.44
X-ray crystallographic studies on butyryl-ACP reveal flexibility of the structure around a putative acyl chain binding site. Structure (2002) 1.41
Neurological and behavioral abnormalities, ventricular dilatation, altered cellular functions, inflammation, and neuronal injury in brains of mice due to common, persistent, parasitic infection. J Neuroinflammation (2008) 1.41
Vaccines against Toxoplasma gondii: challenges and opportunities. Mem Inst Oswaldo Cruz (2009) 1.39
Maternal inheritance and stage-specific variation of the apicoplast in Toxoplasma gondii during development in the intermediate and definitive host. Eukaryot Cell (2005) 1.37
P2X7 receptor-mediated killing of an intracellular parasite, Toxoplasma gondii, by human and murine macrophages. J Immunol (2010) 1.33
Genetic and epigenetic factors at COL2A1 and ABCA4 influence clinical outcome in congenital toxoplasmosis. PLoS One (2008) 1.32
Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy. Arch Ophthalmol (2008) 1.30
Identification of a sporozoite-specific antigen from Toxoplasma gondii. J Parasitol (2011) 1.28
IL-33 receptor (T1/ST2) signalling is necessary to prevent the development of encephalitis in mice infected with Toxoplasma gondii. Eur J Immunol (2010) 1.27
A Burkholderia pseudomallei toxin inhibits helicase activity of translation factor eIF4A. Science (2011) 1.27
The shikimate pathway and its branches in apicomplexan parasites. J Infect Dis (2002) 1.25
Severe congenital toxoplasmosis in the United States: clinical and serologic findings in untreated infants. Pediatr Infect Dis J (2011) 1.25
Analysis of protein solvent interactions in glucose dehydrogenase from the extreme halophile Haloferax mediterranei. Proc Natl Acad Sci U S A (2006) 1.19
Lipoic acid metabolism in microbial pathogens. Microbiol Mol Biol Rev (2010) 1.18
Parasite regulation by host hormones: an old mechanism of host exploitation? Trends Parasitol (2005) 1.16
Scavenging of the cofactor lipoate is essential for the survival of the malaria parasite Plasmodium falciparum. Mol Microbiol (2007) 1.14
Clinical manifestations of ocular toxoplasmosis. Ocul Immunol Inflamm (2011) 1.13
Natural killer T-cell autoreactivity leads to a specialized activation state. Blood (2008) 1.11
Novel triazine JPC-2067-B inhibits Toxoplasma gondii in vitro and in vivo. PLoS Negl Trop Dis (2008) 1.10
Impact of visual impairment on measures of cognitive function for children with congenital toxoplasmosis: implications for compensatory intervention strategies. Pediatrics (2006) 1.10
Increased prevalence of the pfdhfr/phdhps quintuple mutant and rapid emergence of pfdhps resistance mutations at codons 581 and 613 in Kisumu, Kenya. Malar J (2010) 1.10
The essential GTPase YphC displays a major domain rearrangement associated with nucleotide binding. Proc Natl Acad Sci U S A (2006) 1.10
Maternal serologic screening to prevent congenital toxoplasmosis: a decision-analytic economic model. PLoS Negl Trop Dis (2011) 1.09
Expression, purification and crystallization of the Plasmodium falciparum enoyl reductase. Acta Crystallogr D Biol Crystallogr (2003) 1.09
Longitudinal study of new eye lesions in treated congenital toxoplasmosis. Ophthalmology (2007) 1.09
Targeting malaria with specific CDK inhibitors. Biochim Biophys Acta (2005) 1.09
Substrate specificity and mechanism from the structure of Pyrococcus furiosus galactokinase. J Mol Biol (2004) 1.07
Novel N-benzoyl-2-hydroxybenzamide disrupts unique parasite secretory pathway. Antimicrob Agents Chemother (2012) 1.07
Genetic analysis of influences on survival following Toxoplasma gondii infection. Int J Parasitol (2002) 1.04
Towards an immunosense vaccine to prevent toxoplasmosis: protective Toxoplasma gondii epitopes restricted by HLA-A*0201. Vaccine (2010) 1.04
Oral oocyst-induced mouse model of toxoplasmosis: effect of infection with Toxoplasma gondii strains of different genotypes, dose, and mouse strains (transgenic, out-bred, in-bred) on pathogenesis and mortality. Parasitology (2011) 1.02
Substrate-induced conformational changes in Bacillus subtilis glutamate racemase and their implications for drug discovery. Structure (2005) 1.01
Development of colorimetric microtiter plate assay for assessment of antimicrobials against Acanthamoeba. J Clin Microbiol (2005) 1.01
Longitudinal study of new eye lesions in children with toxoplasmosis who were not treated during the first year of life. Am J Ophthalmol (2008) 1.00
Lipidomic analysis of Toxoplasma gondii reveals unusual polar lipids. Biochemistry (2007) 1.00
Toll-like receptor-4-mediated macrophage activation is differentially regulated by progesterone via the glucocorticoid and progesterone receptors. Immunology (2008) 0.99
Targeting the Lipid Metabolic Pathways for the Treatment of Malaria. Drug Dev Res (2010) 0.98
Cataracts in congenital toxoplasmosis. J AAPOS (2007) 0.98
Studies of Toxoplasma gondii and Plasmodium falciparum enoyl acyl carrier protein reductase and implications for the development of antiparasitic agents. Acta Crystallogr D Biol Crystallogr (2007) 0.98
In vitro correlates of Ld-restricted resistance to toxoplasmic encephalitis and their critical dependence on parasite strain. J Immunol (2002) 0.97
The catalytic copper of peptidylglycine alpha-hydroxylating monooxygenase also plays a critical structural role. Biophys J (2005) 0.97
T. gondii RP promoters & knockdown reveal molecular pathways associated with proliferation and cell-cycle arrest. PLoS One (2010) 0.96
Fatty Acid synthesis as a target for antimalarial drug discovery. Comb Chem High Throughput Screen (2005) 0.96
Functional characterization of the acyl carrier protein (PfACP) and beta-ketoacyl ACP synthase III (PfKASIII) from Plasmodium falciparum. Mol Biochem Parasitol (2002) 0.96
Source attributions of heavy metals in rice plant along highway in Eastern China. J Environ Sci (China) (2011) 0.96
Validation of a modified method for Bxb1 mycobacteriophage integrase-mediated recombination in Plasmodium falciparum by localization of the H-protein of the glycine cleavage complex to the mitochondrion. Mol Biochem Parasitol (2010) 0.95
Identification and development of novel inhibitors of Toxoplasma gondii enoyl reductase. J Med Chem (2010) 0.95
Molecular target validation, antimicrobial delivery, and potential treatment of Toxoplasma gondii infections. Proc Natl Acad Sci U S A (2012) 0.95
Evidence for mitochondrial-derived alternative oxidase in the apicomplexan parasite Cryptosporidium parvum: a potential anti-microbial agent target. Int J Parasitol (2004) 0.95
Host genetic and epigenetic factors in toxoplasmosis. Mem Inst Oswaldo Cruz (2009) 0.95
Overexpression of biotin synthase and biotin ligase is required for efficient generation of sulfur-35 labeled biotin in E. coli. BMC Biotechnol (2010) 0.95
Structure and mechanism of imidazoleglycerol-phosphate dehydratase. Structure (2005) 0.94
Toxoplasma gondii HLA-B*0702-restricted GRA7(20-28) peptide with adjuvants and a universal helper T cell epitope elicits CD8(+) T cells producing interferon-γ and reduces parasite burden in HLA-B*0702 mice. Hum Immunol (2011) 0.94
Differential reactivity between two copper sites in peptidylglycine α-hydroxylating monooxygenase. J Am Chem Soc (2010) 0.94
The unusual mitochondrial compartment of Cryptosporidium parvum. Trends Parasitol (2005) 0.93
Differential modulation of TLR3- and TLR4-mediated dendritic cell maturation and function by progesterone. J Immunol (2010) 0.93
Triazine Inhibits Toxoplasma gondii tachyzoites in vitro and in vivo. Antimicrob Agents Chemother (2005) 0.92
Plasmodium falciparum apicoplast transit peptides are unstructured in vitro and during apicoplast import. Traffic (2011) 0.92